全文获取类型
收费全文 | 4134篇 |
免费 | 268篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 138篇 |
妇产科学 | 112篇 |
基础医学 | 621篇 |
口腔科学 | 31篇 |
临床医学 | 521篇 |
内科学 | 894篇 |
皮肤病学 | 69篇 |
神经病学 | 332篇 |
特种医学 | 60篇 |
外科学 | 409篇 |
综合类 | 56篇 |
一般理论 | 3篇 |
预防医学 | 561篇 |
眼科学 | 45篇 |
药学 | 210篇 |
中国医学 | 4篇 |
肿瘤学 | 314篇 |
出版年
2023年 | 31篇 |
2022年 | 19篇 |
2021年 | 101篇 |
2020年 | 59篇 |
2019年 | 101篇 |
2018年 | 116篇 |
2017年 | 68篇 |
2016年 | 89篇 |
2015年 | 92篇 |
2014年 | 129篇 |
2013年 | 200篇 |
2012年 | 302篇 |
2011年 | 344篇 |
2010年 | 151篇 |
2009年 | 162篇 |
2008年 | 277篇 |
2007年 | 290篇 |
2006年 | 275篇 |
2005年 | 225篇 |
2004年 | 224篇 |
2003年 | 184篇 |
2002年 | 162篇 |
2001年 | 41篇 |
2000年 | 52篇 |
1999年 | 45篇 |
1998年 | 27篇 |
1997年 | 38篇 |
1996年 | 20篇 |
1995年 | 30篇 |
1994年 | 22篇 |
1993年 | 25篇 |
1992年 | 40篇 |
1991年 | 32篇 |
1990年 | 44篇 |
1989年 | 39篇 |
1988年 | 31篇 |
1987年 | 24篇 |
1986年 | 33篇 |
1985年 | 26篇 |
1984年 | 24篇 |
1983年 | 15篇 |
1982年 | 15篇 |
1980年 | 11篇 |
1979年 | 16篇 |
1977年 | 11篇 |
1975年 | 10篇 |
1974年 | 9篇 |
1970年 | 10篇 |
1969年 | 10篇 |
1968年 | 18篇 |
排序方式: 共有4412条查询结果,搜索用时 15 毫秒
1.
2.
We describe two cases of acute‐onset erythema, peeling, and pruritus or tenderness isolated to the palmar surface of the hands. A detailed exposure history revealed significant periods of contact with homemade slime; given the clinical findings and timing of exposure, acute contact dermatitis of the hands was suspected. Symptoms and clinical findings resolved after avoidance of the suspected causative contactants. There are few if any reported cases of contact dermatitis to homemade slime in the literature; this serves to highlight the importance of a thorough exposure history in the evaluation of hand dermatitis. 相似文献
3.
4.
5.
Jonathan I. Silverberg Emma Guttman-Yassky Melinda Gooderham Margitta Worm Stephanie Rippon Sean O’Quinn René van der Merwe Nana Kragh Azra Kurbasic Andreas Wollenberg 《Annals of allergy, asthma & immunology》2021,126(5):576-583.e4
BackgroundAtopic dermatitis (AD) is associated with a substantial burden on quality of life (QoL).ObjectiveTo evaluate the effects of tralokinumab on health-related QoL in patients with moderate-to-severe AD using patient-reported outcomes.MethodsThis was a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging study in adults with moderate-to-severe AD. The patients received subcutaneous tralokinumab or placebo (1:1:1:1) every 2 weeks for 12 weeks and class 3 topical corticosteroid cream or ointment at least once daily from the run-in to end of follow-up. Patient-reported outcome end points were change from baseline to week 12 in the Dermatology Life Quality Index (dermatology life quality index (DLQI); prespecified secondary objective), the Short Form 36 Health Survey (SF-36) version 2, and sleep interference numeric rating scale score (prespecified exploratory objectives).ResultsA total of 204 patients were randomized to placebo (n = 51) or tralokinumab (45 mg, n = 50; 150 mg, n = 51; 300 mg, n = 52). Tralokinumab 300 mg every 2 weeks improved total Dermatology Life Quality Index vs placebo at week 12 (placebo-adjusted mean change, ?3.51 [95% confidence interval, ?6.00 to ?1.02]). At week 12, both the mental component summary (4.23 [0.98-7.47]) and the physical component summary (4.26 [1.83-6.69]) and all 8 domains of the Short Form 36 Health Survey were improved in patients treated with tralokinumab 300 mg vs placebo. Sleep interference was improved at week 12 with all tralokinumab doses vs placebo.ConclusionTralokinumab improved health-related QoL in patients with moderate-to-severe atopic dermatitis, providing further evidence of the value of targeting interleukin-13 in such patients.Trial RegistrationClinicalTrials.gov identifier: NCT02347176; https://clinicaltrials.gov/ct2/show/NCT02347176. 相似文献
6.
Bacteria, Archaea, Eukarya and viruses coexist in the human gut, and this coexistence is functionally balanced by symbiotic or antagonistic relationships. Antagonism is often characterized by the production of antimicrobials against other organisms occupying the same environmental niche. Indeed, close co-evolution in the gut has led to the development of specialized antimicrobials, which is attracting increased attention as these may serve as novel alternatives to antibiotics and thereby help to address the global problem of antimicrobial resistance. The gastrointestinal (GI) tract is especially suitable for finding novel antimicrobials due to the vast array of microbes that inhabit it, and a considerable number of antimicrobial producers of both wide and narrow spectrum have been described. In this review, we summarize some of the antimicrobial compounds that are produced by bacteria isolated from the gut environment, with a special focus on bacteriocins. We also evaluate the potential therapeutic application of these compounds to maintain homeostasis in the gut and the biocontrol of pathogenic bacteria. 相似文献
7.
8.
9.
10.